Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
16
XENE Quote, Financials, Valuation and Earnings
Last price:
$32.11
Seasonality move
:
7.25%
Day range:
$31.15 - $32.10
52-week range:
$26.74 - $46.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
175.06x
P/B ratio:
3.45x
Volume:
938.6K
Avg. volume:
1.3M
1-year change:
-26.36%
Market cap:
$2.4B
Revenue:
--
EPS (TTM):
-$3.23
Analysts' Opinion
-
Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $55.23, Xenon Pharmaceuticals has an estimated upside of 74.68% from its current price of $31.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing 100% downside risk from its current price of $31.62.
Fair Value
-
According to the consensus of 14 analysts, Xenon Pharmaceuticals has 74.68% upside to fair value with a price target of $55.23 per share.
XENE vs. S&P 500
-
Over the past 5 trading days, Xenon Pharmaceuticals has underperformed the S&P 500 by -3.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Xenon Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xenon Pharmaceuticals revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Xenon Pharmaceuticals reported revenues of $7.5M.
Earnings Growth
-
Xenon Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Xenon Pharmaceuticals reported earnings per share of -$0.83.
Enterprise value:
1.9B
EV / Invested capital:
--
Price / LTM sales:
175.06x
EV / EBIT:
--
EV / Revenue:
124.54x
PEG ratio (5yr expected):
-0.51x
EV / Free cash flow:
-9.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-30.08%
Net Income Margin (TTM):
--
Return On Equity:
-31.52%
Return On Invested Capital:
-31.52%
Operating Margin:
-969.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $7.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$160.8M | -$224M | -$293M | -$59M | -$72.7M | |
| EBITDA | -$159.4M | -$221.1M | -$290.4M | -$58.5M | -$72.1M | |
| Diluted EPS | -$2.32 | -$2.71 | -$3.23 | -$0.62 | -$0.83 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $283.3M | $545.6M | $533.4M | $707.2M | $565.5M | |
| Total Assets | $290.7M | $558.1M | $719.9M | $919M | $743.3M | |
| Current Liabilities | $11.5M | $8M | $22.5M | $22.2M | $32M | |
| Total Liabilities | $14.4M | $16.2M | $32.9M | $31.3M | $39.3M | |
| Total Equity | $276.3M | $541.9M | $686.9M | $887.7M | $704M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$117M | -$162.9M | -$196.9M | -$46.2M | -$61.7M | |
| Cash From Investing | -$197.9M | -$201.2M | $242.7M | -$43.2M | $34.5M | |
| Cash From Financing | -- | -- | -- | -- | $1.2M | |
| Free Cash Flow | -$121.9M | -$166.5M | -$199.8M | -$46.4M | -$61.7M | |
XENE
Sector
Market Cap
$2.4B
$34.4M
Price % of 52-Week High
68.74%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-26.36%
-37.36%
Beta (5-Year)
1.098
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$32.10
200-day SMA
Sell
Level
$37.12
Bollinger Bands (100)
Sell
Level
30.64 - 36.48
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Sell
Level
$32.13
Relative Strength Index (RSI14)
Sell
Level
47.16
ADX Line
Sell
Level
17.78
Williams %R
Buy
Level
-80.6569
50-day SMA
Sell
Level
$31.84
MACD (12, 26)
Buy
Level
8.74
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
1.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Stock Forecast FAQ
In the current month, XENE has received 14 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XENE average analyst price target in the past 3 months is $55.23.
-
Where Will Xenon Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xenon Pharmaceuticals share price will rise to $55.23 per share over the next 12 months.
-
What Do Analysts Say About Xenon Pharmaceuticals?
Analysts are divided on their view about Xenon Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xenon Pharmaceuticals is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is Xenon Pharmaceuticals's Price Target?
The price target for Xenon Pharmaceuticals over the next 1-year time period is forecast to be $55.23 according to 14 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XENE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xenon Pharmaceuticals is a Buy. 14 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XENE?
You can purchase shares of Xenon Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xenon Pharmaceuticals shares.
-
What Is The Xenon Pharmaceuticals Share Price Today?
Xenon Pharmaceuticals was last trading at $32.11 per share. This represents the most recent stock quote for Xenon Pharmaceuticals. Yesterday, Xenon Pharmaceuticals closed at $31.62 per share.
-
How To Buy Xenon Pharmaceuticals Stock Online?
In order to purchase Xenon Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
